Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01285414 · ClinicalTrials.gov registry record · Phase 2
Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase 2 study, sponsored by Myrexis.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01285414 is a Phase 2 study that has completed, run by Myrexis. The registered enrollment target is 5 participants.
The verdict
NCT01285414, a Phase 2 study, has completed, sponsored by Myrexis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This, international, multi-center, Phase 2 study of verubulin will be conducted in patients with newly diagnosed Glioblastoma Multiforme (GBM). The study will be conducted in two parts. Part A is an open-label dose finding study that will determine the safety and tolerability of verubulin in combination with standard treatment. Part B is a randomized open-label study that will investigate progression-free survival and overall survival of patients receiving verubulin, at the dose determined in Part A, in combination with standard treatment versus standard treatment alone.
Interventions
- DRUG Verubulin
- DRUG Temozolomide & Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01285414
The ClinicalTrials.gov registry entry for NCT01285414 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Myrexis, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Verubulin is the first listed.
NCT01285414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01285414 about?
NCT01285414 is a clinical study titled "Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme". This, international, multi-center, Phase 2 study of verubulin will be conducted in patients with newly diagnosed Glioblastoma Multiforme (GBM). The study will be conducted in two parts. Part A is an open-label dose finding study that will determine the safety and tolerability of verubulin in combina...
What is the current status of trial NCT01285414?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2010-12. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01285414?
The interventions under investigation include: Verubulin (DRUG), Temozolomide & Radiation Therapy (DRUG).
Who is sponsoring clinical trial NCT01285414?
This trial is sponsored by Myrexis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.